Xu W J, Kang Y M, Zhou L, Chen F F, Song Y H, Zhang C Q
Taishan Medical University, Tai'an 271000, China.
Department of Respiratory Medicine, Qianfoshan Hospital of Shandong Province, Shandong University, Jinan 250014, China.
Zhonghua Zhong Liu Za Zhi. 2017 Feb 23;39(2):146-149. doi: 10.3760/cma.j.issn.0253-3766.2017.02.015.
To explore the clinical application value of prognostic nutritional index(PNI) for predicting overall survival(OS) in patients with advanced non-small cell lung cancer (NSCLC). 123 patients with histologically confirmed non-small cell lung cancer were enrolled in this study, and their clinical and laboratory data were reviewed. The PNI was calculated as 10×serum albumin value+ 5×total lymphocyte countin peripheral blood.Univariate and multivariate analyses were used to identify the potential prognostic factors for advanced NSCLC. PNI of the 123 NSCLC patients was 46.24±6.56. PNI was significantly associated with age, weight loss and pleural effusion (<0.05). However, it showed no relationship with sex, smoking, hemoptysis, chest pain, dyspnea, histological type, clinical stage, and administration of chemotherapy (>0.05). The median OS of the 123 patients was 19.5 months. The median OS in the higher PNI group (PNI≥46.24) and lower PNI group(PNI<46.24) were 25.2 months and 16.4 months, respectively.The 1-year survival rates were 80.6% and 63.9%, and 2-year survival rates were 54.8% and 19.6%, respectively (<0.01). Univariate analysis showed that PNI, age, dyspnea, and weight loss were related to the OS of the advanced NSCLC patients (<0.05). Multivariate analysis identified PNI as an independent prognostic factor for OS of advanced NSCLC (<0.001). PNI can be easily calculated, and may be used as a relatively new prognostic indicator for advanced NSCLC in clinical practice.
探讨预后营养指数（PNI）对晚期非小细胞肺癌（NSCLC）患者总生存期（OS）的预测价值。本研究纳入123例经组织学确诊的非小细胞肺癌患者，并回顾其临床和实验室资料。PNI计算公式为10×血清白蛋白值 + 5×外周血总淋巴细胞计数。采用单因素和多因素分析确定晚期NSCLC的潜在预后因素。123例NSCLC患者的PNI为46.24±6.56。PNI与年龄、体重减轻和胸腔积液显著相关（<0.05）。然而，它与性别、吸烟、咯血、胸痛、呼吸困难、组织学类型、临床分期及化疗应用无关（>0.05）。123例患者的中位OS为19.5个月。PNI较高组（PNI≥46.24）和较低组（PNI<46.24）的中位OS分别为25.2个月和16.4个月。1年生存率分别为80.6%和63.9%，2年生存率分别为54.8%和19.6%（<0.01）。单因素分析显示，PNI、年龄、呼吸困难和体重减轻与晚期NSCLC患者的OS相关（<0.05）。多因素分析确定PNI为晚期NSCLC患者OS的独立预后因素（<0.001）。PNI计算简便，可作为晚期NSCLC临床实践中一个相对较新的预后指标。
